{
    "medicine_id": "c5521a4a5d52d27d2c0364f42a6af5e44de2e517",
    "platform_id": "DB05463",
    "metadata": {
        "name": "Adult Formula 50 60 61 v v Solution",
        "composition": "60 61 v v ISS 1018",
        "clinical_particulars": {
            "therapeutic_indications": "Investigated for use treatment in colorectal cancer hepatitis viral B and lymphoma non hodgkin s ISS 1018 is currently being investigated in combination with HBsAg vaccine as a prophylactic treatment for to prevent Hepatitis B in adults It has also been investigated in combination with rituximab for treatment of b cell or non hodgkin s lymphoma",
            "contraindications": {
                "disease": "NA",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "ISS 1018 is a short synthetic CpG oligodeoxynucleotide CpG ODN with immunostimulatory activity ISS 1018 is an unmethylated CpG motifs in which regions of genomic DNA containing the cytosine guanine dinucleotide does not show methylation of cytosine ISS 1018 signals through Toll like receptor 9 TLR9 to induce the production of immunoglobulin by B cells and interferon IFN alpha IFN beta interleukin 12 IL 12 and tumor necrosis factor alpha TNF alpha by plasmacytoid dendritic cells pDC ISS 1018 CpG ODN also promotes antigen presentation and co stimulatory molecule expression",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}